{{Rsnum
|rsid=4253778
|Gene=PPARA
|Chromosome=22
|position=46234737
|Orientation=plus
|GMAF=0.2534
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=PPARA
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 2.7 | 33.6 | 63.7
| HCB | 0.0 | 0.0 | 100.0
| JPT | 0.0 | 0.0 | 100.0
| YRI | 63.9 | 33.3 | 2.7
| ASW | 33.3 | 52.6 | 14.0
| CHB | 0.0 | 0.0 | 100.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 5.9 | 94.1
| LWK | 51.9 | 42.6 | 5.6
| MEX | 1.7 | 17.2 | 81.0
| MKK | 25.0 | 50.0 | 25.0
| TSI | 4.9 | 44.1 | 51.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4253778
|Name_s=PPARA: IVS7 2498 G>C
|Gene_s=PPARA
|Feature=
|Evidence=PubMed ID:18855529
|Annotation=This SNP in the PPARA gene showed assoziation with heterogeneity in one year outcome in response to beta-blockers in a study in 735 acute coronary syndrome patients.
|Drugs=
|Drug Classes=BETA BLOCKING AGENTS
|Diseases=Coronary Disease
|Curation Level=Curated
|PharmGKB Accession ID=PA162355961
}}

{{PMID Auto
|PMID=19653005
|Title=The combined impact of metabolic gene polymorphisms on elite endurance athlete status and related phenotypes
}}

{{PMID|17317762}} Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.

{{PMID|18401448|OA=1
}} PPAR Genomics and Pharmacogenomics: Implications for Cardiovascular Disease.

{{PMID|18549840|OA=1
}} Cholesterol ester transfer protein, interleukin-8, peroxisome proliferator activator receptor alpha, and Toll-like receptor 4 genetic variations and risk of incident nonfatal myocardial infarction and ischemic stroke.

{{PMID|19422653}} Do PPARGC1A and PPARalpha polymorphisms influence sprint or endurance phenotypes?

{{PMID|20620111}} Variation in the PPARalpha gene in Polish rowers.

{{PMID|21430558}} Association of the peroxisome proliferator-activated receptor alpha gene L162V polymorphism with stage C heart failure.

{{PMID Auto
|PMID=22968028
|Title=[Association of both peroxisome proliferator-activated receptor, gene-gene interactions and the body mass index]
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4253778
|overall_frequency_n=46
|overall_frequency_d=128
|overall_frequency=0.359375
|n_genomes=28
|n_genomes_annotated=0
|n_haplomes=40
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23681449
|Title=Genes for Elite Power and Sprint Performance: ACTN3 Leads the Way
}}

{{PMID Auto
|PMID=23545576
|Title=Association of peroxisome proliferator-activated receptor α/δ/γ with obesity, and gene-gene interaction, in the Chinese Han population
|OA=1
}}

{{PMID Auto
|PMID=23937834
|Title=[Effects related to gene-gene interactions of peroxisome proliferator-activated receptor on essential hypertension]
}}

{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}